NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis $1.17 +0.02 (+1.74%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.51%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Geron Stock (NASDAQ:GERN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Geron alerts:Sign Up Key Stats Today's Range$1.11▼$1.1850-Day Range$1.10▼$1.6252-Week Range$1.09▼$4.84Volume9.86 million shsAverage Volume12.70 million shsMarket Capitalization$745.20 millionP/E RatioN/ADividend YieldN/APrice Target$4.61Consensus RatingModerate Buy Company Overview Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. Read More Geron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreGERN MarketRank™: Geron scored higher than 60% of companies evaluated by MarketBeat, and ranked 352nd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageGeron has only been the subject of 2 research reports in the past 90 days.Read more about Geron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.67% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Geron has recently increased by 7.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Sustainability and ESG1.3 / 5Environmental Score-2.75 Percentage of Shares Shorted10.67% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Geron has recently increased by 7.89%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment-0.29 News SentimentGeron has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Geron this week, compared to 12 articles on an average week.Search Interest20 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows17 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 750% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.42% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock News HeadlinesLeerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) With a $3 PTAugust 1 at 2:38 AM | insidermonkey.comGeron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025July 28, 2025 | businesswire.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 1 at 2:00 AM | Crypto 101 Media (Ad)Leerink Partnrs Predicts Geron's Q4 Earnings (NASDAQ:GERN)July 25, 2025 | americanbankingnews.comCautiously Optimistic: Geron’s Strategic Changes and Growth Prospects Support Buy RatingJuly 21, 2025 | tipranks.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | gurufocus.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GERN Stock NewsJuly 18, 2025 | gurufocus.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | businesswire.comSee More Headlines GERN Stock Analysis - Frequently Asked Questions How have GERN shares performed this year? Geron's stock was trading at $3.54 on January 1st, 2025. Since then, GERN stock has decreased by 66.9% and is now trading at $1.17. How were Geron's earnings last quarter? Geron Corporation (NASDAQ:GERN) posted its earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The business's revenue for the quarter was up 12927.3% on a year-over-year basis. Read the conference call transcript. Who are Geron's major shareholders? Geron's top institutional shareholders include Aberdeen Group plc (1.10%), Nvest Financial LLC (0.05%), Inspire Investing LLC (0.04%) and Ballentine Partners LLC (0.01%). Insiders that own company stock include Olivia Kyusuk Bloom, Scott Alan Samuels, John A Scarlett, Elizabeth G O'farrell, V Bryan Lawlis, Susan Molineaux, Faye Feller and Andrew J Grethlein. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings5/07/2025Today8/01/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN Previous SymbolNASDAQ:GERN CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees229Year FoundedN/APrice Target and Rating Average Price Target for Geron$4.61 High Price Target$9.00 Low Price Target$1.00 Potential Upside/Downside+306.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$174.57 million Net Margins-119.54% Pretax Margin-119.54% Return on Equity-47.86% Return on Assets-26.78% Debt Debt-to-Equity Ratio0.44 Current Ratio7.87 Quick Ratio6.97 Sales & Book Value Annual Sales$76.99 million Price / Sales9.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book2.47Miscellaneous Outstanding Shares636,920,000Free Float589,659,000Market Cap$722.90 million OptionableOptionable Beta0.64 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:GERN) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.